Shares of Twist Bioscience (TWST) climbed sharply on Thursday after the synthetic-DNA specialist revealed a collaboration with Eli Lilly's (LLY) TuneLab drug-discovery platform. By 3:13 p.m. Eastern time, the stock had gained 10.8% to $158.50, adding $15.43 from Wednesday's close. Trading volume was notably elevated, with approximately 2.51 million shares changing hands—about 45% above the three-month average daily volume.
The market's enthusiasm is clear, but the financial impact of the deal is not. Twist's announcement on September 16 positions the company as a provider of antibody-characterization data services for TuneLab, yet it omits key details such as contract value, minimum order commitments, revenue-sharing arrangements, duration, or exclusivity. This leaves investors to base their optimism on potential access to a valuable customer network rather than a concrete revenue stream.
What the Lilly Agreement Actually Entails
Under the agreement, TuneLab participants can order wet-lab antibody services from Twist using preferred protocols and pricing. The resulting characterization data may support AbLab, a TuneLab model designed to predict whether an antibody candidate possesses the properties needed for development. This data can also be contributed back to the platform through its federated-training system, which is intended to preserve the privacy of each company's proprietary information.
Lilly launched TuneLab in September 2025 to provide select biotechnology companies with access to models trained on its proprietary research. At launch, Lilly noted that the initial models drew on data generated from more than $1 billion in research investment. Participating biotechs contribute training data, while a third-party system is designed to keep each company's proprietary information confidential.
For Twist, the commercial rationale is straightforward. AI models can screen candidates, but laboratories still need consistent experimental data to train and validate those models. Every TuneLab participant that selects Twist's preferred workflow becomes a potential services customer. However, the announcement does not specify that participants must use Twist, nor does it indicate any committed purchase volume from Lilly itself.
The Key Metric to Watch
The operating segment most relevant to this agreement is Twist's DNA Synthesis and Protein Solutions, which includes antibody-discovery and characterization work. In the quarter ended June 30, that segment's revenue rose 39% year over year to $56.6 million. Total company revenue increased 23% to $118.4 million, with gross margin reaching 52.8%.
These figures provide a plausible foundation for Thursday's rally: the business line tied most closely to the new agreement was already Twist's faster-growing segment. A useful confirmation would be continued acceleration in services revenue or a measurable increase in characterization volumes after TuneLab customers begin ordering. Without that evidence, the partnership's contribution cannot be separated from growth already underway.
Financial Context and Challenges
The distinction matters because Twist is still working toward breakeven. In the June quarter, the company recorded a GAAP net loss of $35.1 million and an adjusted EBITDA loss of $11.3 million, while holding about $167 million in cash, equivalents, and short-term investments. Management raised fiscal 2026 revenue guidance to $456 million to $457 million and maintained a target of adjusted EBITDA breakeven in the September quarter.
A preferred position within Lilly's ecosystem could improve utilization of Twist's high-throughput infrastructure and bring repeat work from biotech customers. That is an inference from the agreement's design, not company guidance. Preferred pricing could also limit revenue per order, and laboratory demand may take time to follow platform adoption.
What Would Justify the Rally
Thursday's high of $163.70 put the intraday gain above 14% before shares eased. The strongest case for holding that move is that TuneLab becomes a durable distribution channel rather than a one-off collaboration announcement. Evidence would include a disclosed customer count, contracted volume, a material order, faster DNA Synthesis and Protein Solutions growth, or management linking the arrangement to a higher revenue outlook.
The counterargument is that none of those commercial markers exists yet. Twist's release describes access, protocols, and pricing, not backlog. Investors also still need the company to deliver the September-quarter breakeven target while funding growth. The next earnings report should therefore matter more than another partnership logo: it can show whether the existing business is converting revenue growth into operating leverage, and management may provide the first indication of TuneLab-related demand.
As of 3:13 p.m. Eastern on September 17, 2026, the $158.50 quote and 10.8% move are based on delayed Nasdaq regular-session data. Prices may change before the close.
